Products
Etakafusp Biosimilar Fusion Protein (CD8) for Research
Cat No.: GMP-Bios-INN-1190
Anti-CD8 therapeutic antibody (Pre-made Etakafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Etakafusp (development code AB-248) is an antibody fusion protein targeting CD8. It is developed by Asher Therapeutics for solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1190-1mg | 1mg | 3090 |
| GMP-Bios-INN-1190-10mg | 10mg | |
| GMP-Bios-INN-1190-100mg | 100mg | |
| GMP-Bios-INN-1190-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Etakafusp biosimilar, Fusion Protein targeting CD8: Recombinant therapeutic protein targeting CD8/CD8A/CD8a/T-cell surface glycoprotein CD8 alpha chain |
| INN Name | Etakafusp |
| Target | CD8 |
| Format | Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Asher Therapeutics |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
